SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
Back
15 Apr 2024
3:35 p.m.
3:45 p.m.
Jonathan
Barratt
Free Communication
United Kingdom
University of Leicester, Leicester, UK
Add to My Schedule